Morgan Stanley Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $328.00

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its price objective decreased by equities researchers at Morgan Stanley from $348.00 to $328.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an "equal weight" rating on the biotechnology company's stock. Morgan Stanley's target price indicates a potential upside of 9.28% from the company's current price.

Several other equities analysts have also weighed in on the stock. UBS Group cut their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a report on Monday, June 30th. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday. Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price on the stock. Bank of America cut their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Trading Down 0.1%

Shares of UTHR traded down $0.40 during trading hours on Thursday, hitting $300.16. 498,724 shares of the stock traded hands, compared to its average volume of 446,148. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82. The firm has a market capitalization of $13.54 billion, a PE ratio of 11.98, a price-to-earnings-growth ratio of 6.58 and a beta of 0.53. The business has a fifty day moving average of $301.03 and a 200-day moving average of $320.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the prior year, the firm posted $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, equities research analysts expect that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Raymond Dwek sold 3,000 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director owned 1,750 shares in the company, valued at approximately $499,747.50. The trade was a 63.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 76,681 shares of company stock valued at $22,813,739 over the last 90 days. Insiders own 10.30% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. SVB Wealth LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $32,000. Dunhill Financial LLC increased its stake in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in United Therapeutics in the 1st quarter valued at $49,000. Finally, Brooklyn Investment Group increased its stake in United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after buying an additional 98 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.